Research location

San José

Costa Rica

Published trials84

Site observations115

Linked trials published84

Page1 / 2

Research activity in San José

Costa Rica

CureCurrent currently publishes aggregate city-level research activity for this location: 84 trials and 115 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in San José

84 linked trials · page 1 of 2

Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle GlaucomaNCT05696561 · 2025-09-09 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 2 site observations

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729 · 2024-05-24 · 1 site observation

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation

Motiva Flora® Aesthetic Breast Recon® Clinical StudyNCT06146231 · 2023-08-18 · 1 site observation

iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754 · 2018-02-17 · 1 site observation

An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.NCT06230393 · 2024-06-01 · 1 site observation

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 2 site observations

ACTIVE_NOT_RECRUITING

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Randomized Clinical Trial in Parkinson's Disease Patients Using Pluripotent Adipose Stem Cells (PASCs)NCT06141317 · 2023-06-23 · 2 site observations

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerNCT05415215 · 2022-07-05 · 3 site observations

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerNCT05171777 · 2022-04-04 · 2 site observations

American Registry of Ambulatory or Acutely Decompensated Heart FailureNCT05295641 · 2022-04-01 · 2 site observations

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle GlaucomaNCT05280366 · 2022-02-09 · 1 site observation

DOuBLED - Doubling Outcomes by Lung Cancer Early DiagnosisNCT05091437 · 2021-12-30 · 1 site observation

LatAm-FINGERS Initiative for Cognitive ChangeNCT06492967 · 2021-10-27 · 1 site observation

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 3 site observations

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 2 site observations

HRR Prevalence in LatAm PROSPECT StudyNCT04962880 · 2021-04-21 · 1 site observation

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung CancerNCT04742192 · 2021-03-04 · 1 site observation

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04222972 · 2020-07-24 · 1 site observation

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04177108 · 2019-11-25 · 1 site observation

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)NCT04029480 · 2019-10-08 · 1 site observation

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNCT03822468 · 2019-06-11 · 1 site observation

Prevalence of the Eosinophilic Phenotype Among Severe Asthma PatientsNCT03931954 · 2019-05-15 · 1 site observation

Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa RicaNCT04163159 · 2019-01-07 · 1 site observation

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT03735121 · 2018-12-27 · 2 site observations

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)NCT03711032 · 2018-12-24 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134 · 2018-12-06 · 2 site observations

ACTIVE_NOT_RECRUITING

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)NCT03675737 · 2018-11-08 · 3 site observations

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisNCT03523858 · 2018-05-28 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerNCT03337724 · 2018-01-06 · 2 site observations

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT03285763 · 2017-10-25 · 1 site observation

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)NCT03189719 · 2017-07-25 · 3 site observations

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerNCT03072238 · 2017-06-30 · 2 site observations

Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC StudyNCT02789540 · 2016-06-10 · 1 site observation

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).NCT02670083 · 2016-03-22 · 2 site observations

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)NCT02425891 · 2015-06-23 · 2 site observations

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World SettingsNCT02322762 · 2014-12-30 · 1 site observation

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsNCT02075840 · 2014-08-19 · 1 site observation

Latin American Survey of Nutrition and Health / Estudio Latinoamericano de Nutrición y SaludNCT02226627 · 2014-03-01 · 1 site observation

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid ArthritisNCT01952509 · 2013-10-01 · 1 site observation

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVNCT01281813 · 2011-08-08 · 1 site observation

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTXNCT01039688 · 2010-01-01 · 1 site observation

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideNCT00968812 · 2009-09-01 · 1 site observation

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric SubjectsNCT00807846 · 2009-09-01 · 1 site observation

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 DiabetesNCT00909597 · 2009-05-01 · 2 site observations

A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid ArthritisNCT00754572 · 2009-02-01 · 2 site observations

Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for HypertensionNCT00797862 · 2008-11-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.